Clinical Programs


Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome. Therapix is currently recruiting for a Phase IIa study at Yale University entitled “Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome” [ Identifier:NCT03066193] (view more here), and will begin an additional Phase IIa study at Hannover Medical School (view more here).  In addition, the Company is developing THX-ULD01, which targets the high-value and under-served market of mild cognitive impairments.

Display Events
Chart Style
Recent News
Dec 4, 2017

TEL AVIV (Reuters) - Israel’s Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating...

Dec 4, 2017

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, announces the completion of enrollment...

Nov 21, 2017

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, has received...

See More Releases